Dr. Clay Siegall’s has experienced the painful effects of cancer. The executive leader’s father was diagnosed with the disease and went through a five-year battle with the same. Within this period, the zoology student at the University of Maryland started gaining interest in cancer research. He was convinced that there were better ways to handle the disease rather than the predominant methods of chemotherapies and amputations. He notes that patient undergoing the process have a lower chance of surviving the disease. In addition, chemotherapy patients tend to develop anemia owing to the severity of the treatments.
Owing to his experience with the disease, Clay started focusing his studies in the field of cancer therapies. Notably, Clay has a sound educational background. He pursued his post graduate degree in genetics. His rich resume has played an integral role in enhancing his skills in cancer research and developing cancer therapies. Despite facing numerous challenges, Dr. Siegall has been relatively successful in developing cancer drugs that prolong the lives of cancer patients.
During his interview with the Inspirery, Dr. Siegall discussed the various ways through which his company, Seattle Genetics, makes money. According to the executive officer, the major source of the company’s income is its proprietary drugs. Since FDA approved its first ADC drug, ADCETRIS, the company has been able to earn revenues from the sale of the drug to patients around the globe. Presently, the drug is available in over 60 countries. In addition, the company generates income from the sale of licenses to various biotech companies in the cancer therapy sector. This approach has also helped in hastening the process of developing drugs that meet the needs of cancer patients and their families. Earlier, the company depended on funding from investors and the money generated from its initial public offer to run its operations.
About Clay Siegall
Dr. Clay Siegall is a genetics expert and a renowned entrepreneur. The scientist is a co-founder of Seattle Genetics. Clay is an alumnus of George Washington University. His exemplary leadership skills have played a pivotal role in growing Seattle Genetics. He was also heavily involved in developing the world’s first antibody-drug conjugate therapy. The executive leader lives in Seattle with his family.